INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inmune Bio (INMB) and Joint (JYNT). Inmune Bio (INMB) In a report...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)

Inmune Bio (($INMB)) has held its Q1 earnings call. Read on for the main highlights of the call. Inmune Bio’s latest earnings call painted a pictur...

Inmune Bio Advances CORDStrom Amid Funding Pressures

The latest announcement is out from Inmune Bio ( ($INMB) ). On April 29, 2026, INmune Bio Inc. and its UK subsidiary INmune Bio International enter...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INMB	$1.42	+1.43%	206.22K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INMB	$1.42	+1.4%	206.22K
3
4
5
6

INMB

INMB

Get INmune Bio Inc. Data in Excel

Get INmune Bio Inc. Data in Excel